You are here

  • Home
  • Archive
  • Volume 9, Issue 4
  • Changes in ocular signs and symptoms in patients switching from bimatoprost–timolol to tafluprost–timolol eye drops: an open-label phase IV study

Article metrics

Article menu

Download PDFPDF

XML
Research
Ophthalmology
Changes in ocular signs and symptoms in patients switching from bimatoprost–timolol to tafluprost–timolol eye drops: an open-label phase IV study

 

Online download statistics by month:

Online download statistics by month: April 2019 to June 2025

AbstractFullPdf
Apr 201910631059151
May 201922522576
Jun 201912412432
Jul 201910010021
Aug 2019969613
Oct 2019807915
Nov 2019707010
Dec 2019929217
Jan 2020807814
Feb 2020676715
Mar 2020656513
May 2020515142
Jun 2020717115
Jul 2020625521
Aug 2020323110
Sep 2020514323
Oct 2020535111
Nov 2020543721
Dec 2020464229
Jan 2021393622
Feb 2021302818
Mar 2021423913
Apr 2021656514
May 2021495016
Jun 2021464410
Jul 2021363412
Aug 2021373713
Sep 2021454116
Oct 2021454521
Nov 2021373511
Dec 2021747720
Jan 2022343512
Feb 2022939724
Mar 202210610913
Apr 20221181177
May 202212211819
Jun 202293947
Jul 2022726718
Aug 202273739
Sep 2022838412
Oct 2022695511
Nov 2022353215
Dec 202226228
Jan 202321159
Feb 202318184
Mar 202340336
Apr 202324244
May 202324248
Jun 2023262311
Jul 2023232311
Aug 202315138
Sep 202325235
Oct 202314103
Nov 2023272510
Dec 202329264
Jan 202435309
Feb 202423239
Mar 2024313144
Apr 2024262535
May 2024192012
Jun 202423228
Jul 202453536
Aug 2024262567
Sep 202421227
Oct 2024323312
Nov 2024212110
Dec 2024383618
Jan 2025333120
Feb 2025232215
Mar 2025222211
Apr 2025262421
May 202526246
Jun 2025444
Total471945951287